Department of Stomatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, P.R. China.
Department of Orthopedics, The First Affiliated Hospital of Nanchang University, The Artificial Joint Engineering and Technology Research Center of Jiangxi Province, Nanchang, Jiangxi 330200, P.R. China.
Mol Med Rep. 2018 Feb;17(2):3232-3238. doi: 10.3892/mmr.2017.8223. Epub 2017 Dec 8.
Postmenopausal osteoporosis is a common systemic skeletal disease that is associated with estrogen‑deficiency. Bone loss associated with bisphosphonates therapy can increase the risk of developing oral osteonecrosis. Recent studies have indicated that enoxacin may inhibit osteoclast formation and bone resorption via a different mechanism from that of bisphosphonates. Therefore, the authors hypothesized that the use of an enoxacin such as bis‑enoxacin (BE) in association with bisphosphonates may be effective in the treatment of postmenopausal osteoporosis‑associated alveolar bone resorption and reduce the risk of oral osteonecrosis by allowing the dose of bisphosphonates to be reduced. A total of 30 6‑month‑old female Sprague‑Dawley rats were randomly assigned to five groups: The Sham, Vehicle, zoledronic acid (ZOL), low concentrations of BE (BE‑L) and high concentrations of BE (BE‑H) groups. The results demonstrated that the ZOL, BE‑L and BE‑H groups had an increased bone volume/tissue volume, trabecular thickness, mineral apposition rate, mineralizing surface/bone surface and a decreased trabecular separation when compared with the Vehicle group. The microscopic evaluation of histological sections clearly supported the results of the micro‑computed tomography. The number of tartrate‑resistant acid phosphatase‑positive osteoclasts was markedly decreased in the ZOL, BE‑L and BE‑H groups, indicating that BE may inhibit osteoclast formation. The anti‑resorptive effect in the BE‑H group was close to or better than that exhibited by the ZOL group; however, this effect was poorer in the BE‑L group. In conclusion, BE has the potential to block alveolar bone resorption resulting from ovariectomy‑induced osteoporosis in rats in a dose‑dependent manner.
绝经后骨质疏松症是一种常见的全身性骨骼疾病，与雌激素缺乏有关。与双膦酸盐治疗相关的骨丢失会增加发生口腔骨坏死的风险。最近的研究表明，依诺沙星可能通过与双膦酸盐不同的机制抑制破骨细胞形成和骨吸收。因此，作者假设在与双膦酸盐联合使用依诺沙星（如双依诺沙星（BE））可能有效治疗绝经后骨质疏松症相关的牙槽骨吸收，并通过降低双膦酸盐的剂量来降低口腔骨坏死的风险。总共 30 只 6 月龄雌性 Sprague-Dawley 大鼠随机分为五组：假手术组、载体组、唑来膦酸（ZOL）组、低浓度 BE 组（BE-L）和高浓度 BE 组（BE-H）。结果表明，与载体组相比，ZOL、BE-L 和 BE-H 组的骨体积/组织体积、小梁厚度、矿化率、矿化表面/骨表面增加，而小梁分离减少。组织学切片的显微镜评估清楚地支持了 micro-CT 的结果。ZOL、BE-L 和 BE-H 组中抗酒石酸酸性磷酸酶阳性破骨细胞数量明显减少，表明 BE 可能抑制破骨细胞形成。BE-H 组的抗吸收作用接近或优于 ZOL 组，但 BE-L 组的作用较差。综上所述，BE 具有阻断去卵巢诱导的大鼠骨质疏松症引起的牙槽骨吸收的潜力，且呈剂量依赖性。
